GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012
01 Jan 2013-
About: The article was published on 2013-01-01 and is currently open access. It has received 2533 citations till now.
Citations
More filters
Gregory A. Roth1, Gregory A. Roth2, Degu Abate3, Kalkidan Hassen Abate4 +1025 more•Institutions (333)
TL;DR: Non-communicable diseases comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional causes accounted for 18·6% (17·9–19·6), and injuries 8·0% (7·7–8·2).
5,211 citations
TL;DR: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden, while for many cancers, Denmark is closing the survival gap with the other Nordic countries.
2,756 citations
Charles University in Prague1, University of Regensburg2, First Faculty of Medicine, Charles University in Prague3, Imperial College London4, University of Hertfordshire5, Pierre-and-Marie-Curie University6, Autonomous University of Barcelona7, Netherlands Cancer Institute8, Medical University of Vienna9, European Association of Urology10, Medical University of Graz11
TL;DR: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice and the stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment.
1,910 citations
TL;DR: Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.
Abstract: Summary Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer. Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188. Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6–18·0), 23 (31·1%, 95% CI 20·8–42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57–79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62–95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator. Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients. Funding Bristol-Myers Squibb.
1,826 citations
University of Ulsan1, Osaka University2, Taipei Veterans General Hospital3, University Health System4, Chang Gung University5, Samsung Medical Center6, National Taiwan University7, Korea University8, China Medical University (Taiwan)9, Kindai University10, Seoul National University Bundang Hospital11, Keio University12, Kyungpook National University13, Japanese Foundation for Cancer Research14, Seoul National University Hospital15, Yonsei University16, National Cheng Kung University17, National Health Research Institutes18
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
1,512 citations